Display options
Cite
Martínez-Sánchez MV, Periago A, Legaz I, et al. Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. Oncoimmunology. 2015;5(4):e1093721doi: 10.1080/2162402X.2015.1093721.
Martínez-Sánchez, M. V., Periago, A., Legaz, I., Gimeno, L., Mrowiec, A., Montes-Barqueros, N. R., Campillo, J. A., Bolarin, J. M., Bernardo, M. V., López-Álvarez, M. R., González, C., García-Garay, M. C., Muro, M., Cabañas-Perianes, V., Fuster, J. L., García-Alonso, A. M., Moraleda, J. M., Álvarez-Lopez, M. R., & Minguela, A. (2016). Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. Oncoimmunology, 5(4), e1093721. https://doi.org/10.1080/2162402X.2015.1093721
Martínez-Sánchez, María V, et al. "Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing." Oncoimmunology vol. 5,4 (2016): e1093721. doi: https://doi.org/10.1080/2162402X.2015.1093721
Martínez-Sánchez MV, Periago A, Legaz I, Gimeno L, Mrowiec A, Montes-Barqueros NR, Campillo JA, Bolarin JM, Bernardo MV, López-Álvarez MR, González C, García-Garay MC, Muro M, Cabañas-Perianes V, Fuster JL, García-Alonso AM, Moraleda JM, Álvarez-Lopez MR, Minguela A. Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing. Oncoimmunology. 2015 Oct 29;5(4):e1093721. doi: 10.1080/2162402X.2015.1093721. eCollection 2016 Apr. PMID: 27141379; PMCID: PMC4839374.
Copy Download .nbib Format: NLM
Share it on

Oncoimmunology. 2015 Oct 29;5(4):e1093721. doi: 10.1080/2162402X.2015.1093721. eCollection 2016 Apr.

Overexpression of KIR inhibitory ligands (HLA-I) determines that immunosurveillance of myeloma depends on diverse and strong NK cell licensing.

Oncoimmunology

María V Martínez-Sánchez, Adela Periago, Isabel Legaz, Lourdes Gimeno, Anna Mrowiec, Natividad R Montes-Barqueros, José A Campillo, José M Bolarin, María V Bernardo, María R López-Álvarez, Consuelo González, María C García-Garay, Manuel Muro, Valentin Cabañas-Perianes, Jose L Fuster, Ana M García-Alonso, José M Moraleda, María R Álvarez-Lopez, Alfredo Minguela

Affiliations

  1. Immunology Service, Instituto Murciano de investigación biosanitaria (IMIB) and Centro de Investigación Biomédica en Red de enfermedades hepáticas y digestivas (CIBERehd), Hospital Clínico Universitario Virgen de la Arrixaca (HCUVA), El Palmar , Murcia, Spain.
  2. Hematology Service, Hospital Rafael Méndez , Lorca, Murcia, Spain.
  3. Hematology Service, HCUVA , Murcia, Spain.
  4. Pediatric oncology Service, HCUVA , Murcia, Spain.
  5. Hematology Service, Hospital General Universitario Santa Lucía , Cartagena, Murcia, Spain.

PMID: 27141379 PMCID: PMC4839374 DOI: 10.1080/2162402X.2015.1093721

Abstract

Missing self recognition makes cancer sensitive to natural killer cell (NKc) reactivity. However, this model disregards the NKc licensing effect, which highly increases NKc reactivity through interactions of inhibitory killer cell immunoglobulin-like receptors (iKIR) with their cognate HLA-I ligands. The influence of iKIR/HLA-ligand (HLA-C1/C2) licensing interactions on the susceptibility to and progression of plasma cell (PC) dyscrasias was evaluated in 164 Caucasian patients and 286 controls. Compared to controls, myeloma accumulates KIR2DL1

Keywords: HLA-C; HLA-I; KIR; KIR ligands; NK cell activating receptors; NK cell licensing ; missing self; myeloma

References

  1. Immunity. 1997 Dec;7(6):753-63 - PubMed
  2. Curr Opin Immunol. 2012 Apr;24(2):246-51 - PubMed
  3. Cancer Biol Ther. 2009 Dec;8(23):2211-20 - PubMed
  4. J Immunol. 2015 May 1;194(9):4518-27 - PubMed
  5. N Engl J Med. 2011 Mar 17;364(11):1046-60 - PubMed
  6. J Exp Med. 1995 Sep 1;182(3):875-84 - PubMed
  7. J Clin Oncol. 2005 May 20;23(15):3412-20 - PubMed
  8. PLoS One. 2009 Dec 04;4(12):e8132 - PubMed
  9. Blood. 2002 Mar 1;99(5):1853-6 - PubMed
  10. J Exp Med. 1996 Sep 1;184(3):913-22 - PubMed
  11. Blood. 2009 Mar 12;113(11):2434-41 - PubMed
  12. Nat Rev Immunol. 2005 Mar;5(3):201-14 - PubMed
  13. Adv Exp Med Biol. 2009;649:286-99 - PubMed
  14. Blood. 2013 Oct 24;122(17):2935-42 - PubMed
  15. Hum Immunol. 2009 Oct;70(10):854-7 - PubMed
  16. Clin Cancer Res. 2011 Mar 15;17(6):1253-63 - PubMed
  17. Blood. 2007 Oct 1;110(7):2586-92 - PubMed
  18. Int J Cancer. 2009 Jan 15;124(2):367-75 - PubMed
  19. J Immunol. 2002 Jun 15;168(12):6208-14 - PubMed
  20. Clin Vaccine Immunol. 2009 Jan;16(1):142-5 - PubMed
  21. J Clin Invest. 2008 Mar;118(3):1017-26 - PubMed
  22. Transplantation. 1999 Dec 15;68(11):1784-9 - PubMed
  23. Ann Rheum Dis. 2009 Apr;68(4):595-8 - PubMed
  24. Genes Immun. 2006 Oct;7(7):576-82 - PubMed
  25. Curr Opin Immunol. 2004 Oct;16(5):626-33 - PubMed
  26. Adv Cancer Res. 1995;67:155-95 - PubMed
  27. J Immunol. 2007 Jul 15;179(2):854-68 - PubMed
  28. J Biol Chem. 2014 Mar 7;289(10):6969-77 - PubMed
  29. Nature. 2005 Aug 4;436(7051):709-13 - PubMed
  30. Cancer Res. 2007 Sep 15;67(18):8444-9 - PubMed
  31. J Immunol. 2001 Jun 15;166(12):7260-7 - PubMed
  32. Immunol Today. 1993 Oct;14(10):491-9 - PubMed
  33. Am J Hematol. 2011 Dec;86(12):967-73 - PubMed
  34. Blood. 2010 Sep 23;116(12):2033-9 - PubMed
  35. J Immunol. 2007 Nov 1;179(9):5977-89 - PubMed
  36. Immunity. 2006 Aug;25(2):331-42 - PubMed
  37. J Immunol. 2014 Jan 15;192(2):553-7 - PubMed
  38. Genome Res. 2012 Oct;22(10):1845-54 - PubMed
  39. J Immunol. 2013 Oct 15;191(8):3981-5 - PubMed
  40. Clin Immunol. 2010 Apr;135(1):26-32 - PubMed
  41. J Immunol. 2010 Jul 1;185(1):433-41 - PubMed
  42. Immunity. 2001 Feb;14(2):123-33 - PubMed
  43. Clin Cancer Res. 2014 Jul 1;20(13):3390-400 - PubMed
  44. Eur J Immunol. 2004 Jun;34(6):1673-9 - PubMed
  45. Nature. 1986 Feb 20-26;319(6055):675-8 - PubMed
  46. Blood. 2008 Jul 15;112(2):435-43 - PubMed
  47. Science. 1999 Jul 30;285(5428):727-9 - PubMed
  48. Leukemia. 2011 Oct;25(10):1657-61 - PubMed
  49. Transplantation. 2013 Apr 27;95(8):1037-44 - PubMed
  50. Lancet Oncol. 2014 Nov;15(12):e538-48 - PubMed
  51. Blood. 2005 Jan 1;105(1):251-8 - PubMed
  52. Blood. 2011 Jan 6;117(1):98-107 - PubMed
  53. Annu Rev Immunol. 2001;19:197-223 - PubMed
  54. J Exp Med. 2003 Aug 18;198(4):557-67 - PubMed

Publication Types